Currently Viewing:
Currently Reading
New Device, With Localized Drug Delivery to Pancreatic Tumors, Could Reduce AE
February 10, 2016 – Surabhi Dangi-Garimella, PhD
Study Hopes to Resolve Questions About Management of Pre-Cancers of the Breast
February 10, 2016 – Jackie Syrop
Strong Gains for Healthcare and Research in President Obama's 2017 Budget
February 09, 2016 – Surabhi Dangi-Garimella, PhD
Trials and Tribulations Besiege the Virtual Healthcare Revolution
February 09, 2016 – Surabhi Dangi-Garimella, PhD
What We're Reading: Aetna, Cigna Sign Performance-Based Deals With Novartis
February 09, 2016 – AJMC Staff
ASCO Recommends Biomarker Use to Guide Early Breast Cancer Therapy Decisions
February 08, 2016 – Surabhi Dangi-Garimella, PhD
PCPs Diligent With Following USPSTF Recommendations on PSA Testing
February 08, 2016 – Surabhi Dangi-Garimella, PhD
What We Know About California's Right-to-Die Law, Except When It Takes Effect
February 07, 2016 – Mary Caffrey
Considering the Burden on Family Caregivers
February 07, 2016 – Priyam Vora

New Device, With Localized Drug Delivery to Pancreatic Tumors, Could Reduce AE

Surabhi Dangi-Garimella, PhD
Mice administered FOLFIRINOX through the implantable device had greater tumor regression and lower tissue toxicity.
Pancreatic cancer is a disease with dismal survival rates (less than 5%) and the second only to non-small cell lung cancer for cancer-related deaths in the United States. A major challenge with treating this disease has been the stromal milieu that surrounds the solid tumor and forms a rigid, impenetrable barrier for chemotherapy. Now, scientists at the University of North Carolina at Chapel Hill have developed a technology that, at least in animal models, has found an Achilles Heel in these tumors.

The researchers have invented an implantable device that can deliver the highly toxic and promising drug cocktail of folinic acid (leucovorin), fluorouracil, irinotecan, and oxaliplatin (together called FOLFIRINOX), directly to the tumor.

“We use the device to hit the primary tumor hard. It’s an exciting approach because there is so little systemic toxicity that it leaves room to administer additional drugs against cancer cells that may have spread in the rest of the body,” according to senior author Jen Jen Yeh, MD, senior author on the study.

According to the paper, published in the Proceedings of the National Academy of Sciences, the iontophoretic device was surgically implanted onto orthotopic patient-derived pancreatic tumors in mice, and the animals were administered saline or FOLFIRINOX through the device, or saline or FOLFIRINOX intravenously (IV). Tumor volumes were measured following treatment completion.

The authors found that 50% of mice who received FOLFIRINOX through the device had significant tumor regression and 1 mouse had stable disease. The mean log2-fold change in tumor volume were 0.4 in mice that received device FOLFIRINOX, 1.9 for IV FOLFIRINOX, 3 for IV saline, and 2.6 for device saline. Additionally, when the tumor tissues were stained for a cell proliferation marker, Ki-67, mice who received FOLFIRINOX through the device had significantly lower expression of the marker, indicating regression of tumor growth. Another important finding of the study was the reduced levels of tissue toxicity with the implanted device, which indicates that these toxic drugs may be better tolerated by patients, and might even improve their quality of life.

“The beauty of this device is that all of the drug delivery is focused locally, with low delivery to the rest of the body,” said James D. Byrne, PhD, the paper’s first author. “If this works in humans, we hope the device can be used as a plug-and-play approach to delivering the latest, most promising drug regimens for patients who have a dire need for new and better treatments.”

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up